DV
Dividend Vision

ANL — Adlai Nortye Ltd. American Depositary Shares

Adlai Nortye Ltd. American Depositary Shares (ANL)

Total return is -11.7% over the past 2.9 years, 99.5 points behind SPY at 87.8%. Its deepest 1-year drawdown was 51.1%.

Adlai Nortye Ltd. is a clinical-stage pharmaceutical company developing a pipeline of cancer therapeutics, including small molecule and antibody-based drug candidates targeting various tumor types such as rectal, esophageal, pancreatic, and colorectal cancers, along with technology transfer and consulting services. The company does not currently distribute dividends. This security appeals to investors seeking exposure to early-stage oncology drug development with higher risk and potential for significant upside if clinical trials succeed.

ANL key facts

Asset type
Stock
Asset class
Equity
Inception date
09/29/2023
Last close
$13.25
Market cap
$742,508,160
Average volume
56292.0
Beta
1.111
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.11